
HDFC Bank Q1 Results FY26: Q1 PAT Down 1.32% to ₹16,257.91 crore; Revenue Rose 13.73% YoY
Updated: 21 Jul 2025 • 12:21 pm
Posted by:

HDFC Bank Q1 Results FY26: HDFC Bank Limited posted its Q1 results on 19th July 2025. The company posted robust numbers with Q1 PAT standing at ₹16,257.91 crores against a revenue of ₹1,33,054.97 crores. During Q1 FY26, the profit gain of the company was recorded at 1.32% YoY, and revenue growth for the same period was 13.73%. For the full financial year 2025, HDFC Bank’s net profit was ₹67,347.36 crores, and its revenue from operations was ₹3,46,149.32 crores.
HDFC Bank Q1 Results 2025: Extracts of FY25 & FY26 (Consolidated Figures)
| Particulars | Quarter Ended | Year Ended | |
| 30-06-2025 | 30-06-2024 | 31-03-2025 | |
| Revenue from Operations | ₹1,33,054.97 | ₹1,16,996.49 | ₹3,46,149.32 |
| Profit After Tax (PAT) | ₹16,257.91 | ₹16,474.85 | ₹67,347.36 |
(Figures in crores)
HDFC Bank Q1 Results 2026 Highlights: Consolidated Figures (Q1 vs FY25)
- HDFC Bank Limited clocked Q1 FY26 revenue of ₹1,33,054.97 crores vs ₹1,16,996.49 crores.
- On the profit front, HDFC Bank earned a PAT of ₹16,257.91 crore in Q1 FY26. During FY25, the company’s PAT stood at ₹16,474.85 crores.
- PAT dip for the first quarter of FY26 was 1.32% YoY, and revenue growth was 13.73% YoY.
HDFC Bank Share Price Performance
On the opening bell of 21st July 2025, the shares of HDFC Bank Limited opened 1.32% up at ₹1,978.20 per share. However, the initial gains are sustained as of now, and HDFC Bank shares are trading at ₹1,984.80 per share, higher than their opening price.
Considering the long-term performance, HDFC Bank shares have yielded close to 20.81% returns in the past 1-year, and 5-year returns stand at 77.32%. Over the maximum timeframe, HDFC Bank shares provided investors with a 35,849.28% return. However, one must ignore the risk of volatility in the stock market and invest in HDFC Bank shares after thorough research.
For regular stock updates, dividend alerts, and expert verdicts, stay informed with Univest!
Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.
Also Read : Jio Financial Q1 Results 2026: Q1 PAT Soars 3.8% to ₹325 crore; Revenue Rose 47% YoY
Recent Articles
Atul Ltd Q1 Results FY26: Q1 PAT Soars 14.20% to ₹127.77 crore; Revenue Rose 11.80% YoY
LTIMindtree Q1 Results FY26: Q1 PAT Soars 10.61% to ₹1,254.10 crore; Revenue Rose 7.63% YoY
Tata Communications Q1 Results FY26: Q1 PAT Down 42.91% to ₹189.98 crore; Revenue Rose 6.57% YoY
Ceat Q1 Results FY26: Q1 PAT Dropped 27.06% to ₹112.45 crore; Revenue Rose 10.54% YoY
Swastika Castal IPO GMP & Review: Apply or Avoid?
Property Share IPO GMP & Review: Apply or Avoid?
Wipro Q1 Results FY26: Q1 PAT Soars 10.90 % to ₹3,330.40 crore; Revenue Rose 0.78% YoY
Jio Financial Q1 Results 2026: Q1 PAT Soars 3.8% to ₹325 crore; Revenue Rose 47% YoY
Axis Bank Q1 Results 2026: Q1 PAT Jumps 3.8% to ₹5,806.14 crores; NII Surged 0.8% YoY
Waaree Renewable Tech Q1 Results 2026: Q1 PAT Jumps 207% to ₹86.44 crores; Revenue Plunged 155% YoY
Recent Articles
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Recent Posts
Rain Industries Analyst Review May 2026
Finolex Cables Analyst Review May 2026
Bio Medica Laboratories IPO Review: Indore Parenteral Injectable Manufacturer Opens 21 May 2026 at Rs 131-139 on NSE SME
RBL Bank Analyst Review May 2026
Q-Line Biotech IPO Review: India’s IVD Diagnostics Manufacturer Opens 21 May 2026 at Rs 326-343 With GMP Signalling 12-19% Premium
Popular this week
Rain Industries Analyst Review May 2026
Finolex Cables Analyst Review May 2026
Bio Medica Laboratories IPO Review: Indore Parenteral Injectable Manufacturer Opens 21 May 2026 at Rs 131-139 on NSE SME
RBL Bank Analyst Review May 2026
Q-Line Biotech IPO Review: India’s IVD Diagnostics Manufacturer Opens 21 May 2026 at Rs 326-343 With GMP Signalling 12-19% Premium

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
